Astrazeneca Ab

Propellon Therapeutics Inc.

Ontario Institute for Cancer Research (Oicr)

Ontario Institute for Cancer Research

Babu Joseph

Methvin Benjamin Isaac

Ahmed Mamai

Rima Al-Awar

Gennady Poda

David Uehling

Brian Wilson

Pandiaraju Subramanian

Abdelmalik Slassi

Yong Liu

Fupeng Ma

Ian Egle

Joshua Clayton

Michael Prakesch

Carlos Armando Zepeda-Velazquez

Anh My Chau

Krzysztof Swierczek

Iain Watson

Justin-Alexander Morin

Julia Kathleen Stille

Julia Katheleen Stille

The present application is directed to compounds of Formula I:

Substituted carboxamides as inhibitors of WDR5 protein-protein binding

The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners. 

The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

The present invention is directed to compounds of Formula I: Wherein R, R, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators

Compounds in accord with Formula I: wherein R, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.

Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators

Growing community of inventors

Oakville, Canada

Babu Joseph